Liposomal NAD+: Does Oral Absorption Really Work?

"Liposomal NAD+" is marketed as the clever workaround to an inconvenient fact: swallowing NAD+ as a plain powder or capsule doesn't get much intact NAD+ into your blood. Wrap the molecule in tiny fat bubbles — liposomes — and, the pitch goes, you protect it from stomach acid and gut enzymes so it can be absorbed whole. It sounds like sound pharmacology, and the products are priced accordingly.

The honest question is narrower and more useful than the marketing: **is there any direct evidence that liposomal encapsulation actually delivers absorbable NAD+ in humans?** When you go looking, the answer is uncomfortable for the category. There is no published human study showing that a liposomal NAD+ product raises blood NAD+ better than a non-liposomal one — or at all. The "enhanced bioavailability" claims are extrapolated from a different molecule (vitamin C) and from the general idea of liposomes, not from data on liposomal NAD+ itself. This page walks through what's genuinely known.

Why oral NAD+ is a hard delivery problem in the first place

NAD+ (nicotinamide adenine dinucleotide) is a large, charged coenzyme that sits at the center of cellular energy metabolism and DNA repair, and whose tissue levels tend to fall with age — which is the entire rationale for trying to "restore" it ¹. The trouble is that NAD+ is exactly the kind of molecule the gut is built to take apart. It is water-soluble, unstable in the acidic stomach, and too big and polar to cross the intestinal wall efficiently as an intact molecule. Rather than being absorbed whole, dietary NAD+ is largely broken down in the gut into smaller building blocks before anything reaches the bloodstream.

That's why the serious science on raising NAD+ has focused on **precursors** — smaller molecules like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — not on swallowing NAD+ itself. And even the precursors are not simply absorbed intact: a 2025 mouse study using NAD+ metabolomics found that only a small portion of orally administered NMN and NR is directly absorbed from the small intestine, with most of it broken down by gut microbiota and rebuilt into NAD+ indirectly through the liver ². If the small, well-studied precursors are mostly dismantled before absorption, the full NAD+ molecule faces an even steeper climb.

What "liposomal" is actually supposed to do

A liposome is a microscopic sphere with a lipid (fat) shell, the same basic chemistry as a cell membrane. The theory is that encapsulating a fragile, poorly-absorbed compound inside that shell can shield it from stomach acid and digestive enzymes and help ferry it across the gut lining. Lipid-based oral delivery is a legitimate, actively researched pharmaceutical field — reviews describe lipid nanoparticle and liposome systems engineered specifically to improve the oral absorption of difficult drugs ³.

But "the technology is real" is not the same as "it works for this product." Liposomes are notoriously variable: their size, stability, how much active ingredient they actually hold, and whether they survive the gut intact all depend heavily on the specific formulation. A supplement labeled "liposomal" is making a claim about a manufacturing approach, not a guarantee of delivered dose. The relevant question for any given product is whether *that* formulation, at *that* dose, has been shown to put more of the active compound into the body — and for NAD+, that evidence is missing.

The closest real evidence comes from vitamin C — and it's modest

Because there are no human bioavailability trials of liposomal NAD+, the strongest evidence the category can borrow comes from **liposomal vitamin C**, the one nutrient where liposomal oral delivery has actually been tested in randomized human trials. It's an imperfect analogy — vitamin C is a much smaller, more stable molecule than NAD+ — but it's the best real-world read on whether the liposomal idea delivers.

The result is "yes, somewhat, with caveats." A 2025 scoping review of liposomal versus non-liposomal vitamin C found nine of ten studies reported higher bioavailability for the liposomal form, but with wildly different formulations and doses, and — crucially — **none measured how much was actually eliminated in urine**, so it's unclear how much of the extra plasma signal the body truly retained and used ⁴. A representative double-blind randomized crossover trial found liposomal vitamin C raised peak plasma concentration by about 27% and total exposure (AUC) by about 21% over standard vitamin C ⁵ — a real but modest edge, and one funded by industry, for a far easier molecule than NAD+.

So even in the best-studied case, "liposomal" buys a moderate bump in a small, stable vitamin — not a transformation. Reading that across to NAD+, a vastly larger and more fragile molecule with no human data at all, the honest extrapolation is: *unknown, and probably overstated.*

What's actually proven about raising NAD+ orally

Strip away the delivery-system marketing and look at what genuinely works to raise blood NAD+ by mouth, and you land on the precursors — not encapsulated NAD+:

- **Nicotinamide riboside (NR)** is the standout. A landmark 2016 study established that NR is uniquely and orally bioavailable in mice and humans, raising blood NAD+ in a controlled fashion ⁶, and later human pharmacokinetic work confirmed it elevates blood NAD+ predictably and dose-dependently ⁷ — no liposome required. - **Nicotinamide mononucleotide (NMN)** taken orally is well tolerated and shifts nicotinamide metabolites in healthy people ⁸, and reliably raises blood NAD+ in dose-ranging trials — but, as above, mostly via indirect breakdown-and-rebuild rather than intact absorption ².

The blunt takeaway is that the molecules with real human evidence for raising NAD+ are the *plain* oral precursors, not liposomal NAD+. And even for those precursors, reliably raising the NAD+ biomarker has repeatedly failed to translate into proven benefits on energy, cognition, or metabolism — a gap we cover in our NAD+ therapy evidence pillar and in NMN vs NR. A systematic review found the metabolic benefits of NAD+ precursors limited and inconsistent despite reliably raised NAD+ ⁹. If raising the biomarker is the easy part and felt benefit is the hard part, paying a premium for an *unproven* way to raise the biomarker is a poor trade.

So is liposomal NAD+ worth it?

Put the pieces together honestly:

1. Oral NAD+ is poorly absorbed intact, which is a genuine problem the marketing correctly identifies ¹². 2. Liposomal delivery is a real technology that *can* improve oral absorption of some compounds ³ — but its effect is formulation-specific and, even in its best-tested case (vitamin C), modest and incompletely characterized ⁴⁵. 3. There is **no** published human study showing a liposomal NAD+ product raises blood NAD+ better than non-liposomal NAD+, or that it works better than simply taking a proven oral precursor like NR ⁶⁷.

That makes liposomal NAD+ a plausible-sounding idea wrapped around an unproven product. It is not a scam in the sense that liposomes are fake — they aren't — but the specific claim that *this* delivery system meaningfully raises your NAD+ is brand-made, not trial-backed. If raising NAD+ is your goal, the evidence points to inexpensive, well-characterized oral precursors rather than premium-priced encapsulated NAD+, and to keeping expectations realistic about what higher NAD+ actually does. For people considering the parenteral routes instead, we lay out the (also thin) evidence in our NAD+ injections guide and NAD+ IV therapy guide — where the only human data on putting NAD+ directly into the body is a single infusion pilot that measured biochemistry, not outcomes ¹⁰. And to compare products and providers on dose, form, and third-party testing, see our NAD+ rankings hub.

This is consumer education, not medical advice — if you have a medical condition, are pregnant, or take other medications, talk to a clinician before starting any NAD+ product.